Clinical Trials Act 2011Section 2
2. Interpretation
In this Act –
“administer” means give or apply a substance or test article, in its
existing state or after it has been dissolved or dispersed in, or diluted
or mixed with, some other substance used as a vehicle, to a human
being –
(a) orally, by injection, by introduction into the body or in any
other way; or
(b) by external application, whether by direct contact with the
body or not;
“adverse event” means any untoward medical occurrence in a patient
or a subject to whom a medicinal product is administered which does
not necessarily have a causal relationship with the treatment;
92 Acts 2011
“adverse reaction” means any untoward and unintended response to
an investigational medicinal product administered in any dose to a
subject;
“Certificate of Good Manufacturing Practice (GMP)” means a
certificate which purports to show that a manufacturer has effectively
implemented a set of international standards aimed at ensuring that
an investigational medicinal product or medicinal product is
consistently manufactured and controlled to the quality standards
appropriate to their intended use;
“Certificate of Pharmaceutical Product (COPP)” means a certificate
issued in a format recommended by the World Health Organisation
by a drug regulatory authority and purporting to –
(a) indicate that a manufacturer has submitted its manufacturing
site to regular GMP inspections; and
(b) provide details about the product and its manufacture,
including, but not limited to, the marketing authorisation
holder, the active ingredients and excipients, the
manufacturing and packaging sites and whether or not the
product is placed on the market in the country of origin;
“clinical trial” means an investigation in a subject intended –
(a) to discover or verify the clinical or pharmacological effect of
an investigational medicinal product;
(b) to identify any adverse reaction to such a product; or
(c) to study the absorption, distribution, metabolism and excretion
of such a product,
for the purpose of ascertaining the safety or efficacy of the product,
after its administration to the subject;
“conditions and principles of good clinical practice” means the
conditions and principles having their origin in the World Medical
Acts 2011 93
Association Declaration of Helsinki on Ethical Principles for Medical
Research Involving Human Subjects;
“Council” means the Clinical Research Regulatory Council referred
to in section 3;
“Ethics Committee” means the Ethics Committee referred to in
section 7;
“guidelines” –
(a) means guidelines which the Council considers applicable to
the conduct of clinical trials in Mauritius;
(b) includes, but is not limited to, existing international standards
such as the good clinical practice guideline (ICH E6) of the
International Conference on Harmonisation of Technical
Requirements for the Registration of Pharmaceuticals for
Human Use;
“health personnel” includes any person who works in a technical or
scientific capacity in a hospital, dispensary, clinic, laboratory or
medical research centre;
“investigational medicinal product” –
(a) means the pharmaceutical form of a substance, test article or
placebo being tested or used as a reference in a clinical trial;
(b) includes a medicinal product, the importation of which is
permitted in an authorised form and which –
(i) is used, formulated or packaged in a different way;
(ii) is used for an unauthorised indication; or
(iii) is used to gain further information about the authorised
form;
94 Acts 2011
“investigator” means a medical practitioner, or other health
professional acceptable to the Council, who is designated by a
sponsor to be responsible for the conduct of a clinical trial;
“investigator’s brochure” means a compilation of the clinical and
non-clinical data on an investigational medicinal product which are
relevant to the study of the product in a subject;
“law practitioner” has the same meaning as in the Law
Practitioners Act;
“manufacture” has the same meaning as in the Pharmacy Act;
“medical practitioner” means a person registered as a general
practitioner or a specialist under the Medical Council Act;
“medicinal product” means a substance which is manufactured, sold,
supplied, imported or exported for use, wholly or mainly, in any of
the following ways –
(a) by being administered to a human being for a medicinal
purpose;
(b) as an ingredient in the preparation of a substance or article
which is to be administered to a human being or an animal for
a medicinal purpose;
“medicinal purpose” means –
(a) treating or preventing disease;
(b) diagnosing disease or ascertaining the existence, degree or
extent of a physiological condition;
(c) contraception;
(d) inducing anaesthesia; or
(e) preventing or interfering with the normal operation of a
physiological function, whether permanently or temporarily,
and whether by terminating, reducing or postponing, or
Acts 2011 95
increasing or accelerating, the operation of that function or in
any other way;
“Minister” means the Minister to whom responsibility for the subject
of health is assigned;
“nursing officer” means a person registered as a general nurse or a
mental health nurse under the Nursing Council Act;
“officer” means an officer of the Council designated under section 6
and includes the Secretary;
“pharmacist” has the same meaning as in the Pharmacy Act;
“pharmacovigilance” means the science and activities relating to the
detection, assessment, understanding and prevention of adverse
effects or any other drug related problems;
“Pharmacovigilance Committee” means the Pharmacovigilance
Committee referred to in section 9;
“protocol” means a document which describes the objective, design,
methodology, statistical consideration and organisation of a clinical
trial;
“Register” means the register of clinical trials referred to in
section 29;
“Secretary” means the Secretary of the Council designated under
section 6;
“serious adverse event” or “serious adverse reaction” means any
adverse event or adverse reaction which –
(a) results in death;
(b) is life-threatening;
(c) requires hospitalisation or prolongation of existing
hospitalisation;
(d) results in persistent or significant disability or incapacity; or
96 Acts 2011
(e) consists of a congenital anomaly or birth defect;
“site” means a place approved by the Council for the conduct of a
clinical trial;
“sponsor” means a person who assumes responsibility for the
initiation, management and financing of a clinical trial;
“subject” means a human being to whom an investigational
medicinal product is administered for the purposes of a clinical trial;
“supervising officer” means the supervising officer of the Ministry
responsible for the subject of health;
“test article” means any drug (including a biological product for
human use), human food additive, colour additive, or other substance
intended for administration to a human being;
“Trade and Therapeutics Committee” has the same meaning as in the
Pharmacy Act;
“trial licence” means a licence issued under section 13;
“trial master file” means the file referred to in section 23.
PART II - CLINICAL RESEARCH REGULATORY COUNCIL